Skip to content

US · GLMD · BIOTECHNOLOGY

Galmed Pharmaceuticals Ltd. (GLMD) intrinsic value and stock valuation

$4.63as of 2026-11-21 · Mkt cap 4.97M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Galmed Pharmaceuticals Ltd. DCF and intrinsic value

InvestorsCraft values GLMD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GLMD’s statements →

Galmed Pharmaceuticals Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Ramat Gan, TA 5250608 galmedpharma.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-10.31M
20122025
Free cash flow
-$-6.32M
20122025
Total equity
$15.8M-18.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-8.51M-$-6.28M-$-7.49M-$-17.65M-$-32.88M
Net income-$-10.31M-$-7.52M-$-6.91M-$-17.87M-$-32.47M
EPSd-$-2.39M-$-8.09M-$-30.04M-$-10.64M-$-19.8M
Operating cash flow-$-6.32M-$-5.88M-$-6.14M-$-18.5M-$-32.89M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-6.32M-$-5.88M-$-6.14M-$-18.5M-$-32.9M
Total assets$18.6M$18.5M$16.6M$16.6M$36.6M
Total debt$0.00$0.00$40K$210K$230K
Net debt-$-3.98M-$-4.65M-$-2.82M-$-1.8M-$-2.65M
Total equity$15.8M$16.3M$13.9M$13.4M$30.5M
Cash and short-term investments$18.2M$15.3M$12.6M$13.8M$34.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$4.87M$2.98M$3.57M$13M$27.2M
Selling, general and administrative expenses$3.64M$3.3M$3.92M$4.66M$5.66M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.51M$6.28M$7.49M$17.7M$32.9M
Cost and expenses$8.51M$6.28M$7.49M$17.7M$32.9M
Interest income$910K$500K$380K$300K$560K
Interest expense$0.00$10K$10K$210K$40K
Depreciation and amortization$0.00$80K$30K$40K$40K
Ebitda-$-10.31M-$-7.42M-$-6.87M-$-17.62M-$-32.38M
Operating income-$-8.51M-$-6.28M-$-7.49M-$-17.65M-$-32.88M
Total other income/expenses, net-$-1.8M-$-1.24M$580K-$-210K$410K
Income before tax-$-10.31M-$-7.52M-$-6.91M-$-17.87M-$-32.47M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.31M-$-7.52M-$-6.91M-$-17.87M-$-32.47M
Weighted average shares outstanding$4.31M$930K$230K$1.68M$1.64M
Weighted average diluted shares outstanding$4.31M$930K$230K$1.68M$1.64M
Balance sheet
20252024202320222021
Cash and short-term investments$18.2M$15.3M$12.6M$13.8M$34.8M
Net receivables$80K$210K$170K$160K$80K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$18.6M$16.1M$13.2M$14.7M$36.1M
Property, plant and equipment, net$0.00$0.00$120K$340K$550K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$2.12M$3.27M$1.5M$0.00
Total non-current assets$0.00$2.38M$3.39M$1.84M$550K
Total assets$18.6M$18.5M$16.6M$16.6M$36.6M
Accounts payable$2M$1.31M$1.88M$2.56M$4.87M
Short-term debt$0.00$0.00$40K$170K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.85M$2.17M$2.75M$3.09M$5.88M
Long-term debt$0.00$0.00$0.00$40K$230K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$40K$230K
Capital lease obligations$0.00$0.00$40K$210K$230K
Total liabilities$2.85M$2.17M$2.75M$3.14M$6.11M
Common stock$3.41M$740K$210K$70K$70K
Retained earnings-$-210.78M-$-200.47M-$-192.95M-$-186.04M-$-168.17M
Accumulated other comprehensive income (loss)-$-300K-$-420K-$-450K-$-740K-$-170K
Total equity$15.8M$16.3M$13.9M$13.4M$30.5M
Total investments$14.2M$12.8M$13.1M$13.3M$31.9M
Total debt$0.00$0.00$40K$210K$230K
Net debt-$-3.98M-$-4.65M-$-2.82M-$-1.8M-$-2.65M
Cash flow statement
20252024202320222021
Net income-$-10.31M-$-7.52M-$-6.91M-$-17.87M-$-32.47M
Depreciation and amortization$0.00$80K$30K$40K$40K
Stock-based compensation$550K$530K$890K$1.3M$1.89M
Change in working capital$910K-$-730K$130K-$-2.45M-$-2.45M
Accounts receivable$240K-$-190K$340K$300K-$-310K
Inventory$0.00$0.00$0.00-$-300K$310K
Accounts payable$690K-$-570K-$-680K-$-2.31M-$-2.17M
Net cash provided by operating activities-$-6.32M-$-5.88M-$-6.14M-$-18.5M-$-32.89M
Investments in property, plant and equipment$0.00$0.00$0.00-$0.00-$-10K
Acquisitions, net$0.00$0.00-$-1.5M-$-20K$0.00
Net cash used for investing activities-$-3.38M-$-1.11M$800K$17.6M$11.5M
Common stock issued$9.03M$8.79M$6.18M$70K$17.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.03M$8.79M$6.18M$70K$17.4M
Net change in cash-$-660K$1.79M$850K-$-870K-$-4.06M
Cash at end of period$4.11M$4.77M$2.98M$2.13M$3M
Operating cash flow-$-6.32M-$-5.88M-$-6.14M-$-18.5M-$-32.89M
Capital expenditure$0.00$0.00$0.00-$0.00-$-10K
Free cash flow-$-6.32M-$-5.88M-$-6.14M-$-18.5M-$-32.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Galmed Pharmaceuticals Ltd.

        Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

        CEO
        Allen Baharaff
        Employees
        6
        Beta
        0.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Galmed Pharmaceuticals Ltd. (GLMD)?

        InvestorsCraft does not currently publish an intrinsic value for GLMD. How the IC value is calculated.

        Is GLMD undervalued?

        InvestorsCraft does not publish an undervaluation signal for GLMD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.